Consensus Pliant Therapeutics, Inc.

Equities

PLRX

US7291391057

Market Closed - Nasdaq Other stock markets 21:00:00 30/04/2024 BST			5-day change	1st Jan Change
11.82 ^USD	-2.23%		-5.59%	-34.73%

03-12	Pliant Therapeutics, Inc. Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis	CI
03-05	RBC Lifts Price Target on Pliant Therapeutics to $54 From $50, Says Bexotegrast Could Have Multi-Billion-Dollar Revenue Opportunity; Outperform, Speculative Risk Kept	MT

Evolution of the average Target Price on Pliant Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

309a25280cad368591647b9ccaf9b9c.HjmzWVBr-RlT0uCDUCeb3pPFgJfk2TGx3OaKbcI-viI.aU3GOjcHkUwi6pPQJ2zMkr615uK7vAn97qnkHJgIyXBKfsFoNAGzchuK2A~7c8e64b9a2519982dd7e5c4b2d32aead

Analyst Recommendations on Pliant Therapeutics, Inc.

RBC Lifts Price Target on Pliant Therapeutics to $54 From $50, Says Bexotegrast Could Have Multi-Billion-Dollar Revenue Opportunity; Outperform, Speculative Risk Kept	03-05	MT
RBC Cuts Price Target on Pliant Therapeutics to $50 From $53, Keeps Outperform, Speculative Risk	02-28	MT
Oppenheimer Adjusts Pliant Therapeutics Price Target to $47 From $49, Maintains Outperform Rating	02-06	MT
HC Wainwright Adjusts Pliant Therapeutics Price Target to $48 From $52, Maintains Buy Rating	02-05	MT
RBC Trims Price Target on Pliant Therapeutics to $53 From $54, Keeps Outperform, Speculative Risk	11-10	MT
HC Wainwright Adjusts Price Target on Pliant Therapeutics to $52 From $50, Maintains Buy Rating	27/09/23	MT
Oppenheimer Adjusts Pliant Therapeutics Price Target to $52 From $51, Maintains Outperform Rating	10/08/23	MT
RBC Cuts Price Target on Pliant Therapeutics to $54 From $57, Keeps Outperform Rating, Speculative Risk Qualifier	10/08/23	MT
Canaccord Genuity Initiates Pliant Therapeutics at Buy With $48 Price Target	18/05/23	MT
Oppenheimer Adjusts Pliant Therapeutics Price Target to $51 From $44, Maintains Outperform Rating	10/05/23	MT
RBC Trims Price Target on Pliant Therapeutics to $57 From $58, Maintains Outperform Rating, Speculative Risk Qualifier	10/05/23	MT
HC Wainwright Adjusts Price Target on Pliant Therapeutics to $55 From $54, Maintains Buy Rating	01/05/23	MT
Cantor Fitzgerald Adjusts Pliant Therapeutics Price Target to $63 From $52, Maintains Overweight Rating	01/05/23	MT
Baird Initiates Pliant Therapeutics at Outperform With $44 Price Target	13/04/23	MT
HC Wainwright Adjusts Price Target on Pliant Therapeutics to $54 From $53, Keeps Buy Rating	20/03/23	MT
Citigroup Adjusts Price Target on Pliant Therapeutics to $50 From $55, Maintains Buy Rating	13/03/23	MT
JPMorgan Adjusts Pliant Therapeutics Price Target to $47 From $51, Maintains Overweight Rating	10/03/23	MT
Oppenheimer Adjusts Pliant Therapeutics' Price Target to $44 From $43, Maintains Outperform Rating	10/03/23	MT
RBC Trims Price Target on Pliant Therapeutics to $58 From $60, Maintains Outperform Rating, Speculative Risk	10/03/23	MT
SVB Securities Adjusts Pliant Therapeutics' Price Target to $45 From $33, Keeps Outperform Rating	24/01/23	MT
Citigroup Adjusts Pliant Therapeutics Price Target to $55 From $36, Maintains Buy Rating	24/01/23	MT
Needham Adjusts Pliant Therapeutics' Price Target to $45 From $40, Keeps Buy Rating	23/01/23	MT
Cantor Fitzgerald Adjusts Pliant Therapeutics' Price target to $52 From $40, Keeps Overweight Rating	23/01/23	MT
RBC Boosts Price Target on Pliant Therapeutics to $60 From $50, Maintains Outperform Rating, Assigns Speculative Risk Qualifier	23/01/23	MT
Stifel Starts Pliant Therapeutics at Buy With $33 Price Target	14/12/22	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

11.82 USD

Average target price

43 USD

Spread / Average Target

+263.79%

High Price Target

54 USD

Spread / Highest target

+356.85%

Low Price Target

33 USD

Spread / Lowest Target

+179.19%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Pliant Therapeutics, Inc.

RBC Capital Markets
Oppenheimer
HC Wainwright
Canaccord Genuity
Cantor Fitzgerald
Baird
Citigroup
JPMorgan Chase
SVB Securities LLC
Needham & Co.
Stifel Nicolaus
Piper Sandler
Brigantine Advisors

Ratings for Pliant Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar